MDNA — Medicenna Therapeutics Income Statement
0.000.00%
Last trade - 00:00- CA$84.47m
- CA$54.65m
- 15
- 10
- 45
- 12
Annual income statement for Medicenna Therapeutics, fiscal year end - March 31st, CAD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 8.24 | 17.4 | 22.5 | 16.3 | 18.7 |
| Operating Profit | -8.24 | -17.4 | -22.5 | -16.3 | -18.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -8.28 | -17.3 | -22.6 | -10 | -25.5 |
| Net Income After Taxes | -8.28 | -17.3 | -22.6 | -10 | -25.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -8.28 | -17.3 | -22.6 | -10 | -25.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -8.28 | -17.3 | -22.6 | -10 | -25.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.259 | -0.348 | -0.416 | -0.155 | -0.366 |